diabetes week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of diabetes week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Collaborations
Alliance formed to identify genes associated with cardiovascular disease, diabetes and cancer
January 9th, 2006
Affymetrix, Inc., (AFFX) announced that it has entered into a collaboration with Imperial College London and the Medical Research Council (MRC) to discover the genetic variations associated with cancer, cardiovascular disease and diabetes. The agreement is part of Affymetrix' translational medicine program, an initiative designed to accelerate clinical research and improve patient care by helping to bring more effective personalized tests and therapies to market faster. Researchers at Imperial College and the MRC will use Affymetrix GeneChip technology to perform genotyping and gene-expression experiments. The microarray technology will enable them...
Source: diabetes week (2006-01-09)
|
